Browsing Tag: ras-inhibitor

In a Phase 3 trial, the oral drug daraxonrasib roughly doubled median survival in previously treated metastatic pancreatic cancer — 13.2 months versus 6.7 on chemotherapy. Why the first RAS inhibito...